Viewing nowPregabalin Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Joah Pharmaceutical Co., Ltd.

MFDS item code 201706342 · Approved 2017.07.31 · Insurance code 644603750
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive therapy for partial seizures in patients with epilepsy, and is particularly helpful even in cases with or without secondary generalized symptoms. Additionally, it is used for pain relief in patients with fibromyalgia. It is employed to improve various symptoms related to neurological disorders.
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. This medicine is eliminated primarily by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target dose of 600 mg per day. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated by the dosing regimen. b: The supplemental dose refers to an additional dose given as a single dose. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined by renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended. Adolescents aged 12 to 17 years: Use is not recommended.
This medication may increase the risk of suicidal thoughts or behaviors, so patients should be monitored carefully for symptoms of depression, mood changes, or unusual behavior during treatment. If you have an allergy to any of the ingredients, do not take this medication. Diabetic patients should be cautious as dose adjustment of blood sugar control medications may be needed due to weight gain. If symptoms of angioedema appear, such as swelling of the face or around the mouth, discontinue use immediately. Elderly patients may experience dizziness or drowsiness, which increases the risk of accidents, so they should be particularly cautious at the beginning of treatment. Transient visual disturbances or changes in vision may occur, which may improve upon discontinuation of the medication. There is insufficient data available to change the dosage of this medication alone when used in conjunction with other antiepileptic drugs, so caution is necessary. Discontinuation of this medication should not be abrupt, as withdrawal symptoms such as insomnia, headache, and anxiety may arise; therefore, tapering should be done according to a physician's directive. Patients with a history of substance abuse may be at higher risk for abuse of this medication and should be monitored closely. Patients with impaired renal function may require dose adjustment. Patients with severe cardiovascular disease should use caution when administering this medication. When taken with opioid analgesics, there may be an increased risk of central nervous system depression. Patients with respiratory or neurological conditions, renal impairment, or the elderly may be at risk of respiratory depression and may require dose adjustments. Pregnant women should avoid this medication due to the risk of fetal malformation in early pregnancy, and women of childbearing potential should use effective contraception. This medication can cause dizziness and drowsiness, so caution should be taken when driving or operating hazardous machinery. If severe skin rash or allergic reactions occur, discontinue the medication immediately and consult healthcare providers. This medication does not have significant pharmacokinetic interactions with other drugs; however, effects may be enhanced if taken with alcohol or central nervous system depressants. Breastfeeding mothers should consult with healthcare professionals before using this medication due to the potential transfer into breast milk affecting the infant. In case of overdose, symptoms may include drowsiness, confusion, and seizures, necessitating immediate medical treatment. Keep this medication out of reach of children and do not transfer it to another container.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, excessive sweating, misuse, abuse, dependence, respiratory depression, decreased respiratory function, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual dysfunction, agitation, mood instability, decreased emotions, increased emotions, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disorders, sensory abnormalities, sensory impairment, sedation, somnolence, cognitive impairment, nystagmus, language disorders, myoclonus, decreased reflexes, movement disorders, psychomotor agitation, positional dizziness, hyperesthesia, burning sensation, activity tremor, syncope, delirium, decreased mobility, olfactory disturbances, loss of taste, writing difficulties, diplopia, dry eyes, eye swelling, decreased vision, eye pain, eye strain, increased tear production, ocular irritation, mydriasis, visual depth perception changes during vibration, strabismus, bright visual field, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast hypertrophy, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased blood creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased blood potassium, weight loss, increased blood creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, apathy, delirium, paralysis (facial paralysis), affective disorders, drowsiness, confused state, agitation, restlessness, worsening of seizures
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is best to maintain a storage temperature between 15 to 30 degrees Celsius. This will help preserve the efficacy and safety of the medication.
A hard capsule with a reddish-brown upper part and a white lower part containing white powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Joah Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.